

FRONTIERS IN ANTI-INFECTIVE AGENTS

VOLUME 6

Editors:

Parvesh Singh
Vipan Kumar
Rajshekhar Karpoormath

Bentham Books

Frontiers in Anti-Infective Agents

(Volume 6)

Edited by

Parvesh Singh

*School of Chemistry and Physics
University of Kwa-Zulu Natal (UKZN)
Westville Campus, Durban
South Africa*

Vipan Kumar

*Department of Chemistry
Guru Nanak Dev University
Amritsar
India*

&

Rajshekhar Karpoormath

*Department of Pharmaceutical Chemistry
University of Kwa-Zulu Natal (UKZN)
Westville Campus, Durban
South Africa*

Frontiers in Anti-Infective Agents

Volume # 6

Editors: Parvesh Singh, Vipin Kumar and Rajshekhar Karpoormath

ISSN (Online): 2705-1080

ISSN (Print): 2705-1072

ISBN (Online): 978-981-4998-42-0

ISBN (Print): 978-981-4998-43-7

ISBN (Paperback): 978-981-4998-44-4

©2021, Bentham Books imprint.

Published by Bentham Science Publishers Pte. Ltd. Singapore. All Rights Reserved.

BENTHAM SCIENCE PUBLISHERS LTD.

End User License Agreement (for non-institutional, personal use)

This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the book/echapter/ejournal (“**Work**”). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.

Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: permission@benthamscience.net.

Usage Rules:

1. All rights reserved: The Work is the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.
2. You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it.
3. The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.

Disclaimer:

Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided "as is" without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction, advertisements or ideas contained in the Work.

Limitation of Liability:

In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.

General:

1. Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of Singapore. Each party agrees that the courts of the state of Singapore shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).
2. Your rights under this License Agreement will automatically terminate without notice and without the

need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.

3. You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.

Bentham Science Publishers Pte. Ltd.

80 Robinson Road #02-00

Singapore 068898

Singapore

Email: subscriptions@benthamscience.net



CONTENTS

| | |
|---|-----------|
| PREFACE | i |
| LIST OF CONTRIBUTORS | iii |
| CHAPTER 1 REVERSE VACCINOLOGY APPROACHES FOR RAPID VACCINE DESIGN AGAINST EMERGING INFECTIOUS DISEASES | 1 |
| <i>Arindam Mitra</i> | |
| INTRODUCTION | 1 |
| Reverse Vaccinology | 3 |
| Vaccines Developed by Using Reverse Vaccinology | 4 |
| Reverse Vaccinology for Intracellular Pathogens | 6 |
| Reverse Vaccinology Strategies to Design A Vaccine Against SARS-CoV-2 | 7 |
| Bioinformatics Based Vaccine Predictive Tools | 8 |
| Challenges of Reverse Vaccinology | 10 |
| A Paradigm Shift in Vaccinology - Reverse Vaccinology 2.0 | 10 |
| CONCLUSION | 11 |
| CONSENT FOR PUBLICATION | 11 |
| CONFLICT OF INTEREST | 12 |
| ACKNOWLEDGEMENTS | 12 |
| REFERENCES | 12 |
| CHAPTER 2 LEPTOSPIROSIS - A COMPLETE REVIEW | 19 |
| <i>N. Ramalakshmi, S. Arunkumar and A. Puratchikody</i> | |
| HISTORY OF LEPTOSPIROSIS | 20 |
| EPIDEMIOLOGY | 21 |
| MORPHOLOGY | 22 |
| CLINICAL FEATURES OF LEPTOSPIROSIS | 23 |
| CURRENT TREATMENT | 24 |
| DRUG TARGETS | 24 |
| CURRENTLY AVAILABLE DIAGNOSTIC TESTS | 27 |
| IgM-Enzyme Linked Immunosorbent Assay | 27 |
| IgM-dipstick Assay | 28 |
| The Indirect Hemagglutination Assay (IHA) | 28 |
| Molecular Diagnosis | 28 |
| Molecular Typing | 28 |
| NATURAL PRODUCTS FOR THE TREATMENT OF LEPTOSPIROSIS | 29 |
| SYNTHETIC ANALOGS FOR THE TREATMENT OF LEPTOSPIROSIS | 34 |
| BIOCHEMICAL PARAMETERS | 38 |
| HISTOPATHOLOGICAL CHANGES IN LEPTOSPIROSIS | 39 |
| IN SILICO STUDIES FOR LEPTOSPIRAL DRUGS | 40 |
| BIOMARKERS IN LEPTOSPIROSIS | 41 |
| PREVENTION AND CONTROL | 42 |
| CONCLUSION | 42 |
| CONSENT FOR PUBLICATION | 43 |
| CONFLICT OF INTEREST | 43 |
| ACKNOWLEDGEMENT | 43 |
| REFERENCES | 43 |
| CHAPTER 3 PHAGE THERAPY AS AN ALTERNATIVE ANTIBACTERIAL THERAPY | 50 |
| <i>Nachimuthu Ramesh, Prasanth Manohar, Archana Loganathan, Kandasamy Eniyan and Sebastian Leptihn</i> | |

| | |
|---|-----|
| INTRODUCTION | 51 |
| History: From the Vault | 52 |
| Basics: Phage Life cycle and Phage Biology | 54 |
| Taxonomical Classification of Bacteriophages | 56 |
| Family: Ackermannviridae | 57 |
| Family: Autographiviridae | 57 |
| Family: Chaseviridae | 58 |
| Family: Demereciviridae | 58 |
| Family: Drexleriviridae | 58 |
| Family: Herelleviridae | 58 |
| Family: Myoviridae | 58 |
| Family: Podoviridae | 59 |
| Family: Siphoviridae | 59 |
| Genus: Lilyvirus | 59 |
| Key Advantages and Disadvantages of Phage Therapy | 59 |
| PHAGE THERAPY: PHAGE RESISTANT BACTERIAL EVOLUTION | 60 |
| Phage Cocktails and Personalized Phage Therapy | 62 |
| Phage-Antibiotics Synergy | 64 |
| IMMUNOLOGICAL ASPECTS OF PHAGE THERAPY | 65 |
| Phage Transverse and Human Phageome | 65 |
| Phage-Immune System Crosstalk | 67 |
| Bacteriophage and Innate Immune Response | 68 |
| Bacteriophage and Humoral Immune Response | 69 |
| Synergistic Interaction of the Human Immune System and Phages | 70 |
| Pharmacodynamic and Pharmacokinetic Aspect of Phage Therapy | 70 |
| Phage Pharmacodynamics | 71 |
| Phage Pharmacokinetics | 72 |
| Adsorption | 72 |
| Distribution | 72 |
| Excretion and Metabolism | 74 |
| APPLICATION OF PHAGE THERAPY AGAINST BACTERIAL INFECTIONS | 74 |
| Phage Therapy for Wound Infections | 74 |
| Phage Therapy for Cystic Fibrosis | 79 |
| Phage Therapy for Urinary Tract Infections | 83 |
| Phage Therapy for Respiratory Infections | 86 |
| CHALLENGES AND THE FUTURE OF PHAGE THERAPY | 93 |
| CONCLUSION | 95 |
| CONSENT FOR PUBLICATION | 95 |
| CONFLICT OF INTEREST | 95 |
| ACKNOWLEDGEMENTS | 95 |
| REFERENCES | 95 |
| CHAPTER 4 QUORUM SENSING INHIBITORS FROM NATURAL PRODUCTS: A NEW ANTI-INFECTIVE APPROACH | 111 |
| <i>Debaprasad Parai, Pia Dey and Samir Kumar Mukherjee</i> | |
| ANTIMICROBIAL RESISTANCE AND ITS MECHANISMS | 112 |
| CURRENT UPDATE ON ANTIMICROBIAL RESISTANCE IN CHRONIC BACTERIAL INFECTIONS | 113 |
| QUORUM SENSING AND ITS IMPORTANCE IN BACTERIAL VIRULENCE | 116 |
| QUORUM SENSING INHIBITORS FROM NATURAL PRODUCTS | 118 |
| Phytochemicals | 120 |

| | |
|--|-----|
| Marine Microorganisms | 123 |
| <i>Marine Gram-positive Bacteria</i> | 123 |
| <i>Marine Gram-Negative Bacteria</i> | 124 |
| <i>Marine Fungi and Their Derivatives</i> | 125 |
| MODES OF ACTION OF QSIS | 126 |
| Inactivation of QS Receptor | 126 |
| Inhibition of QS Signals Synthesis | 126 |
| Degradation of QS signals | 127 |
| Combined Application of Anti-QS Agents and Antibiotics | 128 |
| FUTURE PERSPECTIVE | 128 |
| CONSENT FOR PUBLICATION | 129 |
| CONFLICT OF INTEREST | 130 |
| ACKNOWLEDGEMENTS | 130 |
| REFERENCES | 130 |
| CHAPTER 5 NITROGEN AND OXYGEN-BASED HETEROCYCLES AS POTENTIAL | |
| ANTI-INFECTIVE AGENTS | 139 |
| <i>Shaik Baji Baba, Naresh Kumar Katari and Rambabu Gundla</i> | |
| INTRODUCTION | 139 |
| 1,2,4-TRIAZOLES | 142 |
| Antifungal Activity | 144 |
| Antibacterial Activity | 148 |
| Antiviral Agents | 151 |
| ISATIN: (1H-INDOLE- 2,3-DIONE) | 152 |
| Antiviral Agents | 153 |
| Antibacterial Agents | 154 |
| Antitubercular Agents | 156 |
| COUMARIN | 158 |
| Antibacterial Agents | 160 |
| Antiviral Activity | 164 |
| SUMMARY AND PERSPECTIVE | 167 |
| CONSENT FOR PUBLICATION | 168 |
| CONFLICT OF INTEREST | 168 |
| ACKNOWLEDGEMENTS | 168 |
| REFERENCES | 168 |
| SUBJECT INDEX | 177 |

PREFACE

Pathogens have historically affected human populations worldwide, resulting in epidemics and pandemics of different origins and epidemiology, as well as high mortality rates. Despite advancements in detection mechanisms and treatment of many known diseases through the development of novel drugs, the increase in the pace of evolution of drug resistance remains the greatest obstacle in drug design and discovery. The most recent threat to mankind is the SARS-coronavirus-2 (COVID-19), a viral zoonosis, which is difficult to diagnose due to many symptomatic similarities to influenza. Approaching the virus *via* a standardised treatment protocol has been inefficacious due to its rapid mutation, either being more virulent or becoming drug-resistant. The viral infection has engulfed the world in a fight response, in search of an appropriate vaccine or treatment to reduce the risk of infection and loss of human life. Biomolecular engineering and molecular bio-computing have been our greatest tools in drug discovery and development. It has enabled the repurposing of existing drugs by understanding the structure-activity relationship and pharmacokinetic properties against new targets or biological systems.

The book offers an insightful perspective on the most up-to-date developments and research engaged in the combat against pathogens and COVID-19. The contributions from distinguished researchers and leaders in their field are a critical analysis of vaccine development strategies, novel heterocyclic drug scaffolds, the history and biology of infection, and natural products as quorum sensors.

The chapter by Arindam Mitra emphasises reverse vaccinology approaches in vaccine design, intuitively targeting multiple pathogens, including the novel coronavirus, to combat the current pandemic of COVID-19. It also highlights the major advantages of reverse vaccinology for the discovery of novel vaccines with reduced time and cost in development. The second chapter by N. Ramalakshmi *et al.* is a critical review of leptospirosis and its treatment. The current remedies for milder cases of leptospirosis involve antibiotic administration *viz* penicillin, ampicillin, cefmetazole, oxalactam, ceftizoxime, and cefotaxime. This review summarizes the most recent literature on synthetic lead molecules, natural product chemotherapies, and drug targets. The third chapter by Nachimuthu Ramesh *et al.* sheds light on phage therapy and its evolution from lab to bedside endpoints in treating patients. The history and fundamentals of phage biology and its significance in treating infectious diseases have been provided, with commercialization strategies undertaken by the pharmaceutical industry. The fourth chapter by Debaprasad Parai *et al.* focuses on quorum sensing inhibitors (QSIs) from natural products. Quorum sensing is a signalling process, which regulates the expression of several virulence factors in both gram-negative and gram-positive bacteria *via* an autoinducing loop. When a critical bacterial cell density is reached, a complex of regulatory proteins and specific signalling molecules enable the autoinduction of the quorum sensor and the expression of the target genes. This chapter provides a literature review describing the various QSIs obtained from natural sources and their role as anti-infective agents. The fifth chapter by Shaik Baji Baba *et al.* reveals the importance of nitrogen and oxygen-based heterocycles as potential anti-infective agents. It details the development of 1,2,4-triazoles, isatin, and coumarin-based anti-infective agents. Structure-activity relationship studies provide scope for future researchers to develop the most effective and least toxic anti-infective agents.

We would like to acknowledge the expert contributions of the authors mentioned in the review articles in accomplishing this book, which forms an updated base platform for novel drug discovery and development against infective agents. Each author has been recognised as

ii

a dynamic leader in their field and we wish them well for their future research. We reserve a special recognition for the Bentham Science Publishing team, particularly Mrs. Fariya Zulfqar (Manager Publications) and Mr. Mahmood Alam (Editorial Director), for the timely production of the 6th volume and promotion of this scientific collaboration.

Parvesh Singh

School of Chemistry and Physics
University of Kwa-Zulu Natal (UKZN)
Westville campus, Durban
South Africa

Vipan Kumar

Department of Chemistry
Guru Nanak Dev University
Amritsar
India

&

Rajshekhar Karpoormath

Department of Pharmaceutical Chemistry
University of Kwa-Zulu Natal (UKZN)
Westville Campus, Durban
South Africa

List of Contributors

| | |
|------------------------------|--|
| A. Puratchikody | University College of Engineering, Bharathidasan Institute of Technology Campus, Anna University, Tiruchirappalli, India |
| Archana Loganathan | Antibiotic Resistance and Phage Therapy Laboratory, School of Bio Sciences and Technology, Vellore Institute of Technology, Vellore, India |
| Arindam Mitra | Department of Microbiology, School of Life Science and Biotechnology, Adamas University, Kolkata, India |
| Debaprasad Parai | Department of Microbiology, University of Kalyani, Kalyani, West Bengal, India |
| Kandasamy Eniyan | Antibiotic Resistance and Phage Therapy Laboratory, School of Bio Sciences and Technology, Vellore Institute of Technology, Vellore, India |
| N. Ramalakshmi | C.L Baid Metha College of Pharmacy, Chennai, India |
| Nachimuthu Ramesh | Antibiotic Resistance and Phage Therapy Laboratory, School of Bio Sciences and Technology, Vellore Institute of Technology, Vellore, India |
| Naresh Kumar Katari | School of Chemistry & Physics, College of Agriculture, Engineering & Science, Westville Campus, University of KwaZulu-Natal, P Bag X 54001, Durban-4000, South Africa Department of Chemistry, School of Science, GITAM Deemed to be University, Hyderabad, Telangana 502329,, India |
| Pia Dey | Department of Microbiology, University of Kalyani, WB, India- 741235 |
| Prasanth Manohar | Zhejiang University-University of Edinburgh (ZJU-UoE) Institute, Zhejiang University, Haining, Zhejiang, P.R.China and The Second Affiliated Hospital Zhejiang University (SAHZU), School of Medicine, Hangzhou, P.R.China |
| Rambabu Gundla | School of Chemistry & Physics, College of Agriculture, Engineering & Science, Westville Campus, University of KwaZulu-Natal, P Bag X 54001, Durban-4000, South Africa |
| S. Arunkumar | SRM Modinagar College of Pharmacy, Modinagar, India |
| Samir Kumar Mukherjee | Department of Microbiology, University of Kalyani, Kalyani, West Bengal, India |
| Sebastian Leptihn | Antibiotic Resistance and Phage Therapy Laboratory, School of Bio Sciences and Technology, Vellore Institute of Technology, Vellore, India Department of Infectious Diseases, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, P.R. China Infection Medicine, Biomedical Sciences, Edinburgh Medical School, College of Medicine and Veterinary Medicine, The University of Edinburgh, 1 George Square, Edinburgh, EH8 9JZ, United Kingdom |
| Shaik Baji Baba | School of Chemistry & Physics, College of Agriculture, Engineering & Science, Westville Campus, University of KwaZulu-Natal, P Bag X 54001, Durban-4000, South Africa |

CHAPTER 1**Reverse Vaccinology Approaches for Rapid Vaccine Design Against Emerging Infectious Diseases****Arindam Mitra^{1,*}**¹ *Department of Microbiology, School of Life Science and Biotechnology, Adamas University, Kolkata, India*

Abstract: Reverse vaccinology uses computational approaches to identify potential vaccine candidates. With the increasing pace of genome sequencing, it is possible to identify all potential antigens from any sequenced pathogen. Reverse vaccinology uses computational data to identify potential antigens, express those potential antigens, and then screen them further for protective immune response. Thus, reverse vaccinology offers several advantages and enables identifying novel antigens even if the expression level is low or not abundant. Besides, reverse vaccinology approaches offer reduced time and reduced cost for the development of vaccines compared to conventional vaccination methods. Such a timely, speedy, and economical process for developing vaccines without compromising safety and immunogenicity is the urgent need of the hour to combat many emerging pathogens, including SARS-CoV-2. This chapter summarizes approaches and challenges in developing vaccines against many emerging pathogens, including SARS-CoV-2, by employing this innovative strategy.

Keywords: Bioinformatics, COVID-19, Pathogen, Reverse vaccinology, SARS-CoV-2, Vaccine design.

INTRODUCTION

Vaccines are one of the most successful and cost-effective prophylactic measures for improving the quality of health and saving lives from a wide range of infectious diseases worldwide [1, 2]. Eradication of smallpox and significant reduction of global polio cases are outstanding examples of successful vaccination programs where vaccines have significantly reduced mortality and the global burden of infectious diseases. Vaccines are weakened or attenuated from microorganisms or components, which, when introduced into an individual, stimulates the body's immune response and protects against an infectious disease

* **Corresponding author Arindam Mitra:** Department of Microbiology, School of Life Science and Biotechnology, Adamas University, Kolkata, India; Tel: +917305956643; E-mail: arindam.mitra@adamasuniversity.ac.in

caused by the pathogen or similar pathogens. Vaccinology focuses on vaccine development and the effect of vaccines on public health [3]. The classical steps of vaccine development include isolation, culture, and the weakening of a pathogen. Inoculation of a weakened or killed pathogen or a microbe component stimulates a protective immune response in the host. Purified components, such as capsules, recombinant proteins, or weakened toxins also confer protective immunity. Louis Pasteur designed this vaccinology approach of isolation, inactivation, and injection of the agent responsible for the disease. By reducing the pathogen's virulence or inhibiting the replication of a pathogen, the pathogen would be safer for hosts without compromising the immunogenicity of the pathogen. Targeting microbial components, such as capsules, toxins, and surface proteins, reduces the virulence of a given pathogen. This kind of vaccine strategy depends on the body's immune response to combat infectious diseases. It was successful against many infectious diseases such as smallpox, polio, mumps, measles, and rubella. Convalescent plasma therapy (CBT), also known as serum therapy or passive immune therapy, is another proven age-old therapeutic strategy. It depends on protective antibody responses from blood (sera and lymphocytes) from convalescent patients [4]. CBT treatment was successful against diphtheria, tetanus, pneumonia, anthrax, plague, tularemia, among many others [5]. In addition, this therapeutic strategy is employed against many emerging viral diseases, such as Ebola, SARS-CoV, and more recently against SARS-CoV-2 [6, 7]. Fig. (1) highlights classical approaches for vaccine development and convalescent plasma therapy against infectious diseases.




Fig. (1). Classical approaches for the development of vaccines and therapeutics.

However, there are certain limitations in the traditional approach for developing vaccines. Many infectious diseases such as tuberculosis, HIV, malaria, and others do not have an effective vaccine yet. In many cases, the development of a vaccine by the classical method is not feasible due to the lack of proper media for growing a given pathogen. It is difficult or not possible to express a given target antigen, as in meningitis and AIDS. The classical method is also not helpful in developing vaccines based on antigens that elicit strong autoimmune reactions or strains that are highly variable or where the mechanisms of pathogenesis are not well understood. Sometimes, the most expressed proteins may not be ideal vaccine candidates, or the antigens expressed *in vitro* are different from those expressed *in vivo*. Besides, the traditional method of developing vaccines can be time-consuming, and not all antigens can be made pure in adequate amounts for vaccine testing. Conventional vaccine development would not be effective against pathogens that do not induce immunity post-infection. The approach would not apply in cases of chronic diseases including AIDS, tuberculosis, gastritis and hepatitis [8].

Reverse Vaccinology

The sequencing of the first microbe, *Haemophilus influenzae*, in 1995 opened up new possibilities for vaccine design [9]. With the availability of whole-genome sequence of many pathogens at an incredible speed using next-generation sequencing platforms, it is now possible to identify all potential protein antigens *in silico* that may be antigenic or immunogenic without actually culturing the pathogen. Using specific criteria of predictive algorithms and combining tools of bioinformatics and biotechnology, it is also possible to screen the exhaustive list of all potential antigens down to few candidate antigens that can eventually move to safety and immunogenicity testing. In many cases, secreted or extracellular antigens are more likely to be exposed to antibodies than intracellular protein antigens and are likely to be potential vaccine candidates.

Reverse Vaccinology (RV), a term coined by Rino Rappuoli, uses genomics and bioinformatics tools to develop vaccine candidates [10]. This approach enables the identification of all potential protective antigens from sequenced genomes. It facilitates the development of a safe and effective vaccine against any infectious disease that requires a protein antigen to stimulate an immune response [11 - 19]. Choice of algorithms, appropriate criteria for proper selection of antigens, and critical evaluation of the information often determine the success of the RV strategies. Genome-based approaches facilitate identifying novel antigens or unique virulence factors in pathogens, thereby enabling a better understanding of pathogenesis and developing better vaccines. RV-based vaccines are typically targeted based on specific purified components or subunit vaccines and not based

Leptospirosis - A Complete Review

N. Ramalakshmi^{1,*}, S. Arunkumar² and A. Puratchikody³

¹ C.L Baid Metha College of Pharmacy, Chennai, India

² School of Pharmacy, Satyabama Institute of Science and Technology, Chennai, India

³ University College of Engineering, Bharathidasan Institute of Technology Campus, Anna University, Tiruchirappalli, India

Abstract: Leptospirosis is a rare but neglected bacterial infection that affects people and animals. It is caused by bacteria of the genus *Leptospira*. The disease was reported as early as 1886 by Adolf Weil. Leptospirosis may cause kidney damage, meningitis, liver failure, respiratory distress, and even death when it is not treated. Occupations at risk include surfers, slaughterhouse workers, farmers, sewer workers and, people working on derelict buildings. Amjad Islam *et al.* had reported that among Asian countries, its highest prevalence is found in India. In 2015, Federico Costa *et al.* estimated that leptospirosis causes 1.03 million cases worldwide each year. The pooled mortality rate is 25%. WHO has estimated that 0.1 to 1 per 100 000 people living in temperate climates are affected each year, with the number increasing to 10 or more per 100 000 people living in tropical climates. It is reported in all continents except Antarctica. Lesser availability of treatment resources is detrimental, and unfortunately, it is commonly reported in lower-middle-income group countries.

The current treatment modalities for milder cases of leptospirosis rely on antibiotic administration viz penicillin, ampicillin, cefmetazole, oxalactam, ceftizoxime, and cefotaxime.

Whereas, in severe cases, intravenous penicillin G has long been the drug of choice; the patients treated with penicillin for the management of this disease are to be monitored throughout the treatment to prevent the severe threat of potential Jarisch-Herxheimer reactions. In particular, this immune-mediated hypersensitivity reaction may occur within 4-5 h after administration of penicillins. Various kinds of human leptospirosis vaccines have been developed, including inactivated whole-cell, outer-envelope, and recombinant vaccines. Of these, only a multivalent inactivated leptospirosis vaccine (killed vaccine) is available in China, Japan, and Vietnam. However, human vaccines for leptospirosis are serovar-specific and require yearly boosters. So there is a need for the development of novel compounds which have leptospirocidal activity. Notably, drugs for treating leptospirosis are minimum; the present research for the development of novel lead compounds for this pathogen is very limited.

* Correspondence author N. Ramalakshmi: C.L Baid Metha College of Pharmacy, Chennai, India; Tel: +91 9840975248; E-mail: ramalakshmi.arunkumar@gmail.com

This review aims to summarize the most recent literature on synthetic lead molecules, natural products for its treatment, drug targets, *etc.*, and provide recommendations to researchers who may encounter difficulties in finding details on the subject.

Keywords: Drug targets, Leptospirosis, Natural products, Synthetic analogs.

HISTORY OF LEPTOSPIROSIS

Leptospirosis is caused by the pathogenic bacteria of the genus *Leptospira*. This zoonotic disease is prevalent in every continent, except in the Polar regions. The tropical climate has highly favorable ecological conditions for transmission of leptospirosis than temperate climate. Even if leptospirosis is primarily considered a tropical disease, it is ubiquitously present in temperate climates due to changes in environmental conditions, and the migration of humans. As a consequence of ever-increasing awareness and high case incidence, this disease has been scheduled as an emerging global public health disease [1]. It is primarily transmitted through water, food, soil, and mud contaminated with the urine of infected animals to the human. When bacteria enter through skin abrasions and mucous membranes of the mouth, eyes, and nose, humans can acquire leptospirosis.

Leptospirosis was recognized as an occupational hazard of rice harvesters in ancient China. In Japan, leptospirosis was termed as *akiyami*, or autumn fever. Larrey, in 1812, identified leptospirosis as *fièvrejaune* among Napoleon's troops at the siege of Cairo in Egypt. Initially, the endemic disease was supposed to be related to the plague but not as contagious. About 100 years ago, workers in Japan and Europe contemporarily isolated *Leptospira* and identified it as a causative agent for the classical syndrome, the Weil's disease. The nineteenth-century brought rational insights into the cause for the outbreak of icteric fever, which was also called by other names like Griesinger's bilious typhoid, bilious or hepatic fever, hepatic typhoid, icteric typhoid, catarrhal icterus, and febrile icterus. Later on, the icteric infection was known as Weil's disease, and it occurs when humans are exposed to direct contact with water, marshy land, wet soil, or mud. In 1879, spirochete species of the *Borrelia* genus were the cause of relapsing fever of leptospirosis. Spirochaetes, later to be identified as leptospire, were discovered by Japanese investigators in field mice and rats in 1915 [2]. Leptospire were isolated from leptospirosis patients that occurred as mixed infections with yellow fever [3, 4]. In the beginning, it was thought that dengue, sandfly fever, and leptospirosis were caused by the same organism. But later, it was confirmed that dengue and sandfly fever were caused by flavivirus and phlebovirus, respectively, and not by leptospirosis [5].

In Western Europe, *Leptospira interrogans* serovars icterohaemorrhagiae was introduced in the 18th century by the westward extension of the range of *Rattus norvegicus* from Eurasia [6]. There was a report published in the landmark Institute of Medicine entitled “Emerging Infections: Microbial Threats to Health in the United States”; herein, leptospirosis was used as an example of an infection that had in the past caused significant morbidity in military personnel deployed in tropical areas [7]. A new infectious disease was identified from cattle in Georgia in 1935. This infection was associated with icterus, bloody urine, and skin necrosis. The mortality rate ranged between 10 and 60 percent. In 1938, it was reported convalescent serum from such infected cattle agglutinated *Leptospira grippotyphosa* in high titer. It was found that the disease was transmitted by mice. Convalescent sera served as an effective means of treatment [8, 9].

Veterinarians, farmers, sewer workers are at high risk of contracting the disease. Recreational activities involving freshwater, foreign travel, or a combination of both spike the chances of being infected with leptospirosis infection [10]. During World War I, outbreaks were confirmed in French, German, and British troops [11]. This is due to favorable conditions conferred by trench warfare which include water and rat manifestation. “Fort Bragg Fever”, a form of leptospirosis, led to hospitalization of 40 soldiers at Ft. Bragg in North Carolina in the summer of 1942 [12]. In 1961, US military troops were also infected with the pathogen. In 1987, Japanese troops were infected during a water-borne outbreak in Okinawa [13].

Recently, a surge has been witnessed in the number of leptospirosis cases partly due to incessant rain, environmental factors such as polluted water, poor waste management, *etc.* in Ernakulam district, Kerala India. Despite the availability of a drug with proven efficacy as prophylactic against leptospirosis, the refusal of people to take the drug, given at free of cost continues to baffle the district health department [14].

EPIDEMIOLOGY

Epidemiological studies on this subject have been conducted worldwide with the purpose to understand the types of risk factors associated with this disease, and what action needs to be taken to prevent further spread out. However, no answers have been provided as to what causes this illness to a specific individual.

The higher incidence of leptospirosis is located in tropical countries like Latin America, India, Southeast Asia [15, 16]. The division of WHO known as Leptospirosis Burden Epidemiology Reference Group (LERG) conducted a systematic literature review that estimated global annual incidence of endemic

Phage Therapy as an Alternative Antibacterial Therapy

Nachimuthu Ramesh^{1,*}, Prasanth Manohar², Archana Loganathan¹, Kandasamy Eniyan¹ and Sebastian Leptihn^{2,3,4}

¹ Antibiotic Resistance and Phage Therapy Laboratory, School of Bio Sciences and Technology, Vellore Institute of Technology, Vellore, India

² Zhejiang University-University of Edinburgh (ZJU-UoE) Institute, Zhejiang University, Haining, Zhejiang, P.R.China and The Second Affiliated Hospital Zhejiang University (SAHZU), School of Medicine, Hangzhou, P.R.China

³ Department of Infectious Diseases, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, P.R. China

⁴ Infection Medicine, Biomedical Sciences, Edinburgh Medical School, College of Medicine and Veterinary Medicine, The University of Edinburgh, 1 George Square, Edinburgh, EH8 9JZ, United Kingdom

Abstract: Antibiotic resistance is one of the growing concerns in healthcare settings. Most of the clinical and community (bacterial) strains have grown immune to almost all the available antibiotics. The discovery of new antibiotics or resurfacing of available antibiotics has failed to outcompete the growing resistance within the bacterial community. Thus, finding an alternative antibacterial modality to treat infectious diseases has become a significant objective among the scientific community around the globe. Phage therapy is one such an antibacterial therapy for the treatment of severe bacterial infections. The bacteriophages (or phage) are viruses that prey on bacteria for their multiplication and survival. Discovery of bacteriophage dates back to the early 1910s when Frederick W. Twort and Felix d'Herelle observed bacteriolytic activity. Before the discovery of antibiotics, phages were the choice of treatment against bacterial infections, but with the inconsistent research, phage therapy lost its importance in the therapeutics. With the emergence of antibiotic resistance, phage therapy and phage research has got a shape to revolutionize the growing bacterial infections. Phage therapy has shown promising results against severe bacterial infections in the circumstances where antibiotic treatment is ineffectual. This emergency has shed light on this forgotten therapy. This chapter will elucidate the history and fundamentals of phage biology and its significance in treating infectious diseases. With the special focus on advancements in phage research and their clinical outcomes which supports the use of phage therapy in humans. It also deals with the

* Corresponding Author Nachimuthu Ramesh: Antibiotic Resistance and Phage Therapy Laboratory, School of Bio Sciences and Technology, Vellore Institute of Technology, Vellore, India; Tel: 9842660673; E-mail: ramesh.n@vit.ac.in

regulatory inputs required for phage therapy and the commercialization strategies undertaken by pharmaceuticals in the globalization of phage medicine. Besides, the authors would like to brief on the personalized phage therapy and their evolution from lab to bedside endpoints for treating the patients and other future perspectives that hold promise.

Keywords: Antibacterials, Antibiotic resistance, Bacteriophages, Bacterial pathogens, *Caudovirales*, Phage resistance, Phage therapy.

INTRODUCTION

Phage therapy is the use of live bacteriophages (or simply phages) to treat infections caused by pathogenic bacteria. Bacteriophages are known to infect and replicate inside the host bacterium. Bacteriophages are thought to be the widespread, abundant and diverse microorganisms on Earth. The use of bacteriophages for the treatment of bacterial infections can be dated back to 1917; when the bacteriophages were found to kill pathogenic bacteria that were causing diarrhoea and cholera. Though there were improvements in bacteriophage exploration in the 1920s, the discovery of penicillin in 1928 and the subsequent introduction of antibiotics in the 1940s had reduced the applications of bacteriophages in therapy [1]. Antibiotics are antibacterial compounds that are used to kill or inhibit bacteria. Since its introduction as an antibacterial agent, antibiotics have saved millions of lives. As the need for antibiotics started increasing, many pharmaceutical companies were involved in large scale drug discovery from the 1950s to early 1990s. Over half a century antibiotic ruled the medicinal world, until, in the late 1990s the problem of antibiotic resistance has shaken the healthcare sector [2]. Unfortunately, the easy availability of antibiotics paved the way for its misuse and overuse, which eventually leads to resistance among bacteria. As the problem of resistance started increasing, the antibiotic developmental pipeline also becomes dry causing a major crisis to treat bacterial infections. The majority of the infections caused by multi-drug resistant (MDR) bacteria are becoming untreatable and the resistance towards last-resort of antibiotics such as carbapenem, colistin and tigecycline are posing serious threats [3].

Untreatable bacterial infections are causing high mortalities throughout the globe and it was estimated that about 10 million deaths per year by 2050 due to antibiotic-resistant infections [1]. The bacteria that cause hospital-acquired infections (HAI), tuberculosis, co-infections and secondary bacterial infections are becoming difficult to treat. This growing antibiotic crisis is causing a huge burden to the patients both economically and health-related. Though few of the major contributing companies have already stopped their search for new antibiotics, there is still a huge sum of funding available for antibiotics research [4]. The

problem with discovering new antibiotics is that there is no guaranty that the bacteria will not develop resistance again. Therefore, there is a need for alternative therapy or non-antibiotic therapy that could be safe, cost-effective, reliable and advantageous. The renewed interest in phage therapy is mainly due to the increasing antibiotic-resistant bacteria and to treat the infections caused by multi-drug resistant bacteria.

History: From the Vault

The historical evidence for the discovery bacteriophages can be dated back to 1880's, even though the scientific literature explaining these bacteria-eaters are very minimal. Accordingly, in 1896 Hankin reported the antiseptic properties in the water samples collected from Jumna and Ganges Rivers in India [5]. Hankin showed that the antiseptic properties in the water could kill the bacteria, *Vibrio cholerae*. In 1901, Emmerich and Löw described a substance that was causing lysis in the autolysed cultures and it might cure experimental infections but no further experiments were reported [6]. Though there were literature evidences about the reports on bacterial autolysis by Scientists, Gamaleya, Malfitano, Kruse, and Pansini in 1900's, there was no concluding evidence about the action of bacteriophages [7]. Successful improvements in bacteriology, especially bacterial cultures, made significant improvements in bacteriophage research as well, where localized bacteriolysis (plaques) was observed in later years.

The year 2015 marks the century into the 'discovery of bacteriophages' because Frederick W. Twort published his bacteriophage research in 1915 which was considered as the beginning of 'modern phage research'. It was Félix d'Herelle who started working with Twort's phenomenon of 'glassy transformation' and it was later described as bacteriophages. In 1917, d'Herelle described about 'microbes' that were able to lysis the bacteria in the liquid cultures and formed patches on the agar surface, which was termed as 'plaques' [8]. d'Herelle considered them as ultraviruses and later named as 'bacteriophages'. At the Pasteur Institute in Paris, d'Herelle started working with dysentery samples (enteric pathogens) where he identified the lysis of pathogenic bacteria and the formation of clear spots (called as virgin spots) by the invisible microbe. His concept of bacteriophages as the bacterial parasite was found logical. He also hypothesised that bacteriophages require living cells to multiply and interpreted the life cycle as, infection, multiplication, release and reinfection. d'Herelle's research was focused on, (i) the biology of bacteriophages- to understand the biological nature of bacteriophages, and (ii) the therapeutic use of bacteriophages- to cure infectious diseases caused by bacteria. Though the biological nature of bacteriophages was not completely understood, the use of bacteriophages in therapy had overshadowed other biological studies. As soon as d'Herelle observed

CHAPTER 4

Quorum Sensing Inhibitors from Natural Products: A New Anti-infective Approach

Debaprasad Parai^{1,*}, Pia Dey² and Samir Kumar Mukherjee²

¹ ICMR-Regional Medical Research Centre, Bhubaneswar, India

² Department of Microbiology, University of Kalyani, Kalyani, West Bengal, India

Abstract: Currently, the World Health Organization (WHO) considers antibiotic resistance a serious threat to the treatment of infectious diseases. Moreover, the WHO has promoted a complex action plan, based on the slogan “no action today, no cure tomorrow” to control the occurrence and spread of resistant strains that include strategic actions for mitigation, prevention and control. In the last 50 years, only three new classes of antibiotics have been approved by WHO and US Food and Drug Administration (FDA), among which the third one was only approved this year and found to be effective against the Gram-negative Enterobacteriaceae group for the first time after 1962. Keeping all the above facts of continuous emergence of antibiotic resistance in planktonic bacteria and in their biofilm counterpart, this book chapter has tried to add some more alternative drug resources by means of natural products, which could ultimately lead to the betterment of humankind. Several recent studies have shown that natural products (mainly phytochemicals) exhibit their antibacterial activity through different mechanisms of action like bacterial membrane damage, inhibition of virulence factors, quorum sensing signalling, inhibition of enzymes and toxins. Quorum sensing is a signalling process to regulate the expression of several virulence factors in both Gram-negative and Gram-positive bacteria via an autoinducing loop. When a critical bacterial cell density is reached, a complex of the regulatory proteins and specific signalling molecules enable the autoinduction of the quorum sensor and the expression of the target genes. Quorum sensing inhibitors (QSIs) interfering with this regulatory network have either been derived from natural sources *viz.* phytochemicals and fungi, or they have been chemically synthesized. In this chapter, we will summarize the updates from the available literature describing the various QSIs obtained from natural sources and their role as anti-infective agents. We will also discuss the feasibility of these sources towards the development of future drugs to cure systematic infections in the human body.

Keywords: Alternative drug, Antibiotic, Antimicrobial resistance, Anti-infective agent, Infectious disease, Natural product, Pathogen, Quorum sensing, Quorum sensing inhibitor, Virulence factor.

* Corresponding author Debaprasad Parai: ICMR-Regional Medical Research Centre, Bhubaneswar, 751023, India; E-mail: debaprasad.bio@gmail.com

ANTIMICROBIAL RESISTANCE AND ITS MECHANISMS

Antimicrobial resistance (AMR) is defined as the inability of the existing drugs to completely eliminate the target microorganisms. After the discovery of the first commercialized antibiotic, penicillin, by Sir Alexander Fleming in 1928, there was no looking back. It was succeeded by some overwhelming discoveries of a wide variety of antibiotics. But eventually, pathogens started developing resistance against existing drugs and later acquired resistance against subsequent newly discovered drugs. The scenario even worsened by the advent of multi-drug resistant (MDR) pathogens which resisted the action of many antibiotics and chemotherapeutic agents. Multi-drug resistance in bacteria occurs by the accumulation of resistance (R) plasmids or transposons, with each gene coding for resistance to a specific agent, and/or by the presence of multidrug efflux pumps which can pump out one or more than one type of drug [1 - 3].

AMR threatens the effective prevention and treatment of an ever-increasing range of infectious microorganisms like bacteria, viruses, parasites and fungi. In nature, antimicrobial resistant organisms are naturally developed with the course of time due to genetic mutations following the natural process of evolution, and then disseminated among humans, animals, food, plants and environment. Among various grounds, some of the common reasons that can lead to the development of AMR are nature's selection pressure, mutation, and horizontal gene transfer (HGT) along with inappropriate use of broad-spectrum antibiotics. It is only in the past few years that gene exchange has been established as a universal property of bacteria that has occurred throughout eons of microbial evolution [4]. Moreover, the importance of HGT in genomic evolution was strengthened by the presence of putative bacterial gene sequences in eukaryotic genomes. Other notable factors contributing to unrestrained occurrences of resistance are identification and distribution of genomic islands carrying genes for pathogenicity along with plasmid-mediated transfer of antibiotic resistance [5]. Most of the bacterial pathogens have evolved into MDR forms with enhanced morbidity and mortality due to high levels of mutation rate [4]. Many MDR strains of *Escherichia coli*, *Staphylococcus aureus*, *Pseudomonas aeruginosa*, *Streptococcus pneumoniae*, *Clostridium difficile*, *Salmonella enterica*, *Mycobacterium tuberculosis*, *Acinetobacter baumannii*, *Klebsiella pneumoniae*, *Neisseria gonorrhoeae* and *Candida auris* have been observed over the past half-century to cause a variety of diseases in humans [6, 7].

AMR is a major threat to public health and leads to economic losses. A global collaborative approach to fight against AMR is required from all concerned sectors that are affected directly or indirectly. The inability to treat common infections is directly rooted with antimicrobial resistance, which, in turn is caused

by the emergence and spread of drug-resistant pathogens that have acquired new resistance mechanisms. Unfortunately, the spread of antibiotic resistance is a complex web where the path is interconnected, including the food chain, healthcare facilities and the environment. The rapid spread of multi- and pan-drug resistant bacteria (also known as “superbugs”) that cause infections, which are not cured by existing antimicrobials like common antibiotics, is a matter of grave concern. Another outstanding factor that influences and enhances AMR is the occurrence of microbial biofilms [8 - 10]. According to World Health Organization (WHO), with the global rise in AMR, the recalcitrant nature of biofilms is becoming a major concern affecting the healthcare setup, threatening medical procedures, endangering sustainable pharmacological progress and ultimately causing an economical burden. The situation further deteriorates due to the lack of new antimicrobials in the clinical pipeline, lack of access to quality antimicrobials and serious antibiotic shortages affecting entire health-care systems. In 2019, WHO identified 32 antibiotics in clinical development that address the WHO list of priority pathogens, out of which only six were designated to be innovative [11]. The world might be on the inception of a “post antibiotic era,” as antibiotics are becoming increasingly ineffective, accompanied by global spread of drug-resistance, which finally ends up producing a more difficult situation in treating infections and causing enormous loss of life. The fundamental approach in treating AMR across the globe primarily lies in the outlook of people towards responsible use of antibiotics [9, 12].

Antimicrobial resistance is reported from all regions of the world. Modern travel of people, animals, and goods accelerates the easy spread of antimicrobial resistance across borders and continents. For example, the rate of resistance towards ciprofloxacin, an antibiotic commonly used to treat urinary tract infections, increased from 8.4% to 92.9% for *E. coli* and from 4.1% to 79.4% for *K. pneumonia*, in countries reporting to the Global Antimicrobial Resistance Surveillance System (GLASS), a program launched to support the global action plan on antimicrobial resistance in collaboration with the WHO AMR Surveillance and Quality Assessment Collaborating Centres Network [13].

CURRENT UPDATE ON ANTIMICROBIAL RESISTANCE IN CHRONIC BACTERIAL INFECTIONS

The presence of large gaps in the existing surveillance system has restricted the prediction of the exact scenario of antibiotic resistance across the globe. The Centres for Disease Control and Prevention (CDC) and WHO are two global surveillance agencies that work tirelessly to control the introduction and spread of infectious diseases along with providing consultation and assistance to other nations and international agencies to assist in improving their disease prevention

CHAPTER 5

Nitrogen and Oxygen-based Heterocycles as Potential Anti-Infective Agents

Shaik Baji Baba², Naresh Kumar Katari^{1,2,*} and Rambabu Gundla¹

¹ Department of Chemistry, School of Science, GITAM Deemed to be University, Hyderabad, Telangana-502329, India

² School of Chemistry & Physics, College of Agriculture, Engineering & Science, Westville Campus, University of KwaZulu-Natal, P Bag X 54001, Durban-4000, South Africa

Abstract: The success of Anti-infective agents (AIAs) is determined by the interaction between a drug and the binding sites. Significant contributions have been made to the synthetic and dynamic relationship between drugs and pharmacodynamics for the past few years. In general, AIAs include antibacterial, antiviral, antifungal, and antimicrobial agents, *etc.* The clinical benefit of using anti-infecting agents significantly impacts bloodstream infections with central venous catheters (CVCs), pregnancy, and lactation. Recent reports suggest income from AIGs formed 30.1% of the total income of hospitality management. However, many more technical difficulties remain, such as acquiring biologically relevant chemical diversity and achieving activity across diverse pathogens, including highly challenging Gram-negative pathogens with safe drugs. This chapter reviewed 1,2,4-triazoles, isatin, and coumarin-based anti-infective agent developments from the past five years and their biological studies against the various bacterial strains based on new challenges on viral and bacterial infections and viruses. SAR studies also discussed the importance of hybrids and substitutions in biology. We believe that this chapter helps future researchers to develop the most effective and less toxic anti-infective agents.

Keywords: Anti-infective agents, Coumarin, Isatin, Toxicity, Triazole.

INTRODUCTION

Viruses include a large group of pathogens, which are the main ones responsible for producing different infectious diseases. More than 40% of the deaths worldwide are associated with various infectious diseases. From the past few dec-

* Corresponding author Naresh Kumar Katari: Department of Chemistry, School of Science, GITAM Deemed to be University, Hyderabad, Telangana, INDIA; & School of Chemistry & Physics, College of Agriculture, Engineering & Science, Westville Campus, University of KwaZulu-Natal, Durban, South Africa; E-mail: dr.n.k.katari@gmail.com

ades, the development of antiviral agents has played a pivotal role in the research. In the past 50 years, antiviral drugs directly targeted viral proteins and inhibited viral activity, showing better activity [1]. The world is facing different dangerous viruses such as Ebola, Spanish flu, cholera, etc. In 2019-2020, we fought with the most destructive virus, COVID-19 [2]. While developed nations were locked down and quarantined, they have also been struggling to establish a new class of antiviral drugs to kill the new type of Coronavirus. For the past few years, infectious diseases have been the leading cause of death worldwide [3]. In the 1940s, penicillin was introduced as an antibacterial agent from natural products. Natural and synthetic antibiotics have significant effects on human health. However, the treatment of viral and bacterial infections is a challenge because of a growing number of viruses and bacteria, which are multidrug-resistant microbial pathogens [4]. Many AIAs have been available in the market for the past few decades, but the need to develop a new class of drugs is required to minimise the side effects and toxicity. Reports from WHO indicate that diseases like pneumonia, an acquired immunodeficiency syndrome (AIDS), chronic liver disease, chronic obstructive lung disease, and neoplastic diseases like stomach cancers, cervical cancers, and liver cancers are the primary cause of human death worldwide. The severity of infectious diseases causes deaths every year due to AIDS (2.5 million), tuberculosis (1.8 million), and other diseases (more than one million due to malaria, dengue, and chikungunya) as per WHO reports [5]. The *Staphylococci*, *Pseudomonas aeruginosa*, and *Enterococci* are significant contributors of nosocomial type infections, which have also increased over the past few years. This infection is also known as hospital-acquired infection and is mainly transmitted *via* healthcare workers, hospital devices, and patients [6].

Antibiotics are the second most needed category of medication used in medical treatment. The mechanism of antibiotics includes bactericidal (bacteria killers) or bacteriostatic (inhibits microorganism multiplication). Most commonly known active bactericidal agents including penicillins, cephalosporins, and aminoglycosides such as neomycin, kanamycin, gentamicin, tobramycin, streptomycin, amikacin, and a few other bactericides are colistin, vancomycin, bacitracin, and polymyxin B. Bacteriostatic agents are clindamycin, sulphonamides, lincomycin, chloramphenicol, trimethoprim, erythromycin, and tetracyclines [7]. At present, inappropriate antibiotic usage and antibiotic resistance are major global issues because of a direct relation between antibiotics and antibiotic resistance developments. More than 85% of *Staphylococcus aureus* strains are resistant to penicillin and β -lactams in USA hospitals. Antimicrobial agents destroy the microorganism's structural parts or performed by interfering in microbial biosynthetic functions. Infective agents like chloramphenicol, tetracyclines, lincomycin, streptomycin, etc., damage the protein synthesis and affect ribosomal subunits.

In 1963, Idoxuridine was the first antiviral drug introduced on the market. After that, nearly 95 antiviral drugs were approved in the past 50 years. Several types of antiviral drugs are developed for medical use to save human beings from viruses.

From 1993 to 2019, more than 110 antiviral drugs have been approved to treat nine different human viral infectious diseases. Few are under clinical trial phases, and thousands of antiviral agents and inhibitors are reported by multiple researchers globally [8]. The approved antiviral drugs are mainly characterised into thirteen functional groups to treat nine human viral infection diseases, shown in Table 1.

Table 1. Characterization of approving antiviral functional groups for nine human infectious viral diseases [8].

| S. No | Viral Infection | Antiviral Agents/Class |
|-------|--|--|
| 1 | Human immunodeficiency virus (HIV) | Protease inhibitors, integrase inhibitors, nucleoside reverse transcriptase inhibitors, acyclic nucleoside phosphonate analogues |
| 2 | Hepatitis B virus | Lamivudine, interferons, nucleoside analogues, <i>etc.</i> |
| 3 | Hepatitis C virus | Ribavirin, NS3/4A protease inhibitors, NS5A inhibitors, NS5B polymerase inhibitors |
| 4 | Herpesvirus infections | 5-substituted 2'-deoxyuridine analogues, pyrophosphate analogues, acyclic guanosine analogues |
| 5 | Influenza virus | Ribavirin, RNA polymerase inhibitors, and neuraminidase inhibitors, matrix two protein inhibitors |
| 6 | Human cytomegalovirus infections | Acyclic guanosine analogues, pyrophosphate analogues, and oligonucleotides |
| 7 | Varicella-zoster virus infections | Acyclic guanosine analogues, 5-substituted 2'-deoxyuridine analogues, and antibodies |
| 8 | Respiratory syncytial virus infections | Ribavirin and antibodies |
| 9 | Human papillomavirus | Imiquimod, podofilox and sinecatechins |

More effective antiviral drugs/vaccines to treat against emerging viruses such as the Ebola virus, Coronavirus, *etc.*, are not available in the present market. In the antiviral drug development journey, most of the approved antiviral agents are chemically synthesised hybrids. However, natural products play a prominent role in developing antivirals by providing insights into chemical compound synthesis for antiviral drugs [9]. Based on their broad spectrum, antiviral agents kill and inhibit the reproduction of viruses.

This chapter highlights the recent developments of 1,2,4-triazoles, isatin, and coumarin-based anti-infective agents such as antiviral and antibacterial agents based on their applications in medicinal chemistry against viral and bacterial strains. Many research studies have been reported from the past few years. All

SUBJECT INDEX

A

- Abortive infection 61
 Acetyl transferase 25
 Acid(s) 28, 36, 40, 60, 61, 69, 72, 120, 122, 125, 126, 127, 128
 caffeic 128
 carboxylic 36
 fatty 126, 127
 Kojic 125
 nucleic 60, 61, 69
 phenolic 120
 phosphoric 28
 Rosmarinic 120
 salicylic 120, 122
 stomach 72
 ursolic 40, 120
Acinetobacter 5, 76, 112, 149
 baumannii 5, 76, 112
 haemolyticus 149
 Acquired immunodeficiency syndrome 140
 Activity 4, 29, 30, 31, 34, 36, 37, 88, 121, 123, 129, 142, 144, 146, 148, 149, 151, 152, 166, 167
 antidepressant 142
 bactericidal 4, 88, 129
 cytochrome P450-dependent enzyme 142
 gyrase 121
 metabolic 129
 protease 123
 Acyl 25, 116, 122, 124, 127, 129
 carrier protein 25
 homoserine lactones (AHLs) 116, 122, 124, 127, 129
 ADP-heptose synthase 27
 Agents 2, 24, 29, 53, 75, 89, 112, 119, 140
 antioxidant 29
 bacteriostatic 140
 chemotherapeutic 112
 prophylactic 53, 75
 Alamin adenosyl transferase 26
Allium sativum 122
 Anthranilate isomerase 25
 Antibacterial therapy 50
 Antibiotic 114, 116
 biosynthesis 116
 resistant pathogens 114
 Anti-infecting agents 139
 Anti-inflammatory activities 165
 Antimicrobial 75, 111, 112, 113, 119, 139, 140, 149, 150, 155, 158, 163
 activities 149, 150, 155, 163
 agents 75, 139, 140, 158
 resistance 111, 112, 113, 119
 Antitubercular agents 156
 Antiviral activity 142, 151, 164, 165, 166
 Apoptosis 38
 Aqueous extract propolis (AEP) 33
Aspergillus 144, 146, 149
 flavus 146
 fumigatus 144, 149
 Assay 4, 27, 28, 165
 cytotoxic activity 165
 enzyme-linked immunosorbent 4, 27
 immune 28
 ATP-dependent Clp protease 27
 Autoimmune reactions 8

B

- Bacillus subtilis* 149, 155, 162
 Bacteria 51, 52, 55, 56, 60, 61, 62, 64, 65, 71, 72, 74, 81, 86, 94, 111, 112, 127, 149
 phytopathogenic 149
 planktonic 111
 Bacterial autolysis 52
B. cepacia complex (BCC) 86
 Bioinformatics 3, 4
 programs 4
 tools 3
 Biosynthesis 24, 26, 124, 125, 142
 ergosterol 142
 inhibited violacein 125
 peptidoglycan 24

pyridoxal phosphate 24
virulence factor 124
Block QS signalling pathway 123
Body homeostasis 68
Burn wound infections 63, 75, 77

C

Campylobacter jejuni 5
Campylobacterosis 5
Candida parapsilosis 144
Catheters, renal urinary 85
Cellular hierarchical communication 126
Central venous catheters (CVCs) 139
Cepacia syndrome 79
Chikungunya 140, 165
Cinnamon tree 123
Click chemistry 153, 157
Clostridium difficile 112
Cobalamin biosynthesis pathway 26
Conjunctivitis 53
Coronavirus, east respiratory 151
 syndrome-related 151
Coronavirus disease 7
Cough 82
Coumarin-based 139, 159
 active pharmaceutical drugs 159
 anti-infective agent developments 139
Cronobacter turicensis 92
Cryptococcus neoformans 144
Curcuma longa 40, 122
Cystic fibrosis 79, 82, 90, 91, 129

D

Damaged barriers 66, 67
Deaths, inhibited cell 166
Dehypoxanthine futalosine cyclase 26
Depolymerases 60
Diabetic 76, 89
 foot infections 76, 89
 wounds 89
Dihydrolipoamide dehydrogenase 27
Disaccharide synthetase 25

Diseases 2, 5, 6, 7, 19, 20, 21, 23, 24, 41, 42,
43, 79, 140, 153, 167, 168
 acute pulmonary 79
 chikungunya virus 153
 neoplastic 140
 severe respiratory 7
DNA 5, 27, 30, 61, 68, 154
 binding affinity 154
 helicase 27
 technology 5

E

Elastase 116, 120, 121, 122, 123, 124, 126
Engineered phage techniques 94
Enterococcus 149, 155, 156, 160
 faecalis 149, 156, 160
 faecium 156
 fecalis 155
Enzyme(s) 4, 24, 26, 27, 39, 40, 79, 111, 119,
127, 128, 155
 depolymerase 79
 dihydrofolate reductase 155
 essential bacterial metalloproteinase 26
 linked immunosorbent assay (ELISA) 4, 27
 nitric oxide synthase 39
Erythromycin 140
Escherichia coli 4, 63, 112, 149, 154, 160,
162, 163
Ethanollic extracts propolis (EEP) 33

F

Fever 20, 23, 153
 relapsing 20
 yellow 20
Fluorescent 4, 22
 activated cell sorting (FACS) 4
 microscopy 22
Food and drug administration (FDA) 111
Functions 61, 121, 140
 cytoplasmic membrane 121
 microbial biosynthetic 140
Fungi 111, 112, 125, 142, 146, 149, 158

endophytic 125
 Furocoumarins 121
Fusarium oxysporum 146

G

Garcinia mangostana 30
 Genome 6, 7, 9, 56, 58, 59, 112
 eukaryotic 112
 Genomic DNA degradation 33
Geotrichum candidum 149
Gibberlla 146
 nicotiancola 146
 saubinetii 146
 Glassy transformation 52
 Global antimicrobial resistance surveillance
 113
 system 113
 Glucosamine 27
 Glutamate cysteine ligase 25
 Growth 127, 153
 inhibition 153
 pathogens 127
 Gut microbiota 56

H

Hachiman systems 61
Haemophilus influenzae 3
 Health promotion activities 114
Helicobacter pylori 129
 Hemorrhages 23, 38
 pulmonary 23
 Hepatic typhoid 20
 Herpesvirus infections 141
 Histopathology 39
 Host specificity-bacteriophages 59
 Human 3, 63, 141, 144, 165
 cytomegalovirus infections 141
 immunodeficiency virus (HIV) 3, 141, 165
 mycobacteria infections 63
 pathogenic fungi (HPF) 144
 Hyaluronidase 67

I

IgM-enzyme linked immunosorbent assay 27
 Immune electrophoresis 28
 Immunological homeostasis 68
 Indirect hemagglutination assay (IHA) 28
 Infected wound tissue 78
 Infections 53, 73, 80, 84, 85, 128, 141, 142,
 153, 166, 167
 gastrointestinal 73
 life-threatening bacterial 128
 mirabilis 85
 pulmonary 80
 renal 84
 skin 53
 staphylococcal 53
 urinary 84
 viral 141, 142, 153, 166, 167
 Infectious 1, 2, 3, 50, 52, 111, 113, 139, 140,
 142, 166
 diseases 1, 2, 3, 50, 52, 111, 113, 139, 140,
 142
 hematopoietic necrosis virus (IHNV) 166
 Inhibition 33, 37, 111, 119, 126, 142, 151,
 160, 163
 anti-microbial 33
 aromatase 142
 enzymatic 119
 helicase 151
 of AHL synthesis 126
 of QS signals synthesis 126
 Inhibitors 61, 141
 integrase 141
 neuraminidase 141
 nucleoside reverse transcriptase 141
 Interstitial nephritis 39
 Intrahepatic cholestasis 39
 Iron chelators 38

K

Klebsiella pneumoniae 63, 112, 149

L

- Lactonases 119, 127
- LasR 122, 123, 124
 - protein 122, 123
 - receptor 124
- Las signalling homeostasis 117
- Leishmania donovani* 6
- Leptospira 22, 23, 26, 27, 28, 33, 36, 37, 38, 40
 - icterohaemorrhagiae 36, 37
 - infected macrophages 38
 - infections 28, 38
 - toxins 23
- Leptospiral antigenic protein 27
- Leptospire 20, 22, 28, 30, 38
- Leptospirocidal activity 19
- Leptospirosis 21, 32, 38, 39
 - fever 32
 - infection 21, 38, 39
- Lipopolysaccharide pathway 24
- Lipoproteins 26, 27
- Liposomal phage cocktails 63
- Liposome-entrapped phages (LEP) 88
- Liver 19, 23, 83, 140
 - cancers 140
 - failure 19, 23
 - function 83
- Low cost-phage therapy 60
- Lung 73, 75, 79, 82, 83, 86, 88, 93
 - function 79, 82
 - infections 73, 79, 82, 86, 88, 93
 - septicemia 93
 - tissue 75
 - transplantation 83
- Lymphocytes 2
- Lysine decarboxylase 27
- Lysis 52, 53, 54, 69, 94
 - induced bacterial 69

M

- Macrophages 66, 88
 - alveolar 88

- Mannose-6-phosphate isomerase 25
- MDR infections 95
- Membrane, hybrid hydrogel 78
- Meningitis 3, 6, 19, 23, 53
- Metabolism 38, 72, 74, 121, 126, 127, 128
 - energy 121
 - nutritional 127
- Methicillin-resistant *Staphylococcus aureus* (MRSA) 63, 74, 76, 89, 90, 93, 115, 148, 151, 155
- Methods, radio immuno assay 28
- Methyltransferase 27
- Microorganisms 1, 74, 112, 118, 119, 123, 124, 129, 140
 - halophilic 123
 - infectious 112, 119
- Microscopic agglutination test 27
- Microsporum gypseum* 144
- Minimum inhibitory concentration (MIC) 29, 30, 31, 33, 34, 39, 53, 62, 148, 149, 151, 154, 156, 157, 160, 161, 162, 163
- Monocytogenes 53
- Mononuclear cell infiltrations 39
- Monotherapy 62
- Morphogenesis 128
- MRSA infections 76
- Multidrug-resistant microbial pathogens 140
- Multifocal interstitial mononuclear 39
 - infiltration 39
- Mycobacterium* 83, 112
 - abscessus 83
 - tuberculosis 112
- Mycoplasma pneumoniae* 6
- Myristica cinnamomea* 120, 122

N

- Necrosis 38, 39, 77
 - hepatocytic 39
- Neisseria gonorrhoeae* 112
- Next generation sequencing (NGS) 56
- NMR spectroscopy 11
- Non-tuberculosis mycobacteria (NTM) 83
- Nose-only inhalation device (NOID) 87

Nucleosidase 126

O

Oregano oil 122

Ornithine decarboxylase 6

Osteomyelitis 6

Outer membrane 26, 27, 40

lipoprotein 40

proteins (OMPs) 26, 27

Outline of reverse vaccinology 11

Oxidoreductases 127

P

Pantoate beta alanine ligase 25

Parapsilosis 144, 146

Pasteur 2, 52

Louis 2

institute 52

Pathogenicity, microbial 118

Pathogenic microbes 120

Pathogen recognition receptors (PRR) 69

Pathways 24, 64

metabolic 64

PCR technique 28

Pellicularia sasakii 146

Penicillin, antibiotic 30

Peptide deformylase 26, 40

Peptidoglycan biosynthesis pathway 24

Peripheral neuropathy 142

Periportal cirrhosis 39

Phage 55, 60, 64, 67, 88

antibiotic synergism 64

monotherapy 64

liposome-entrapped 88

lysogenic 55, 60

proteins 67

Phage therapy 74, 79, 83, 86, 94

applications 94

for cystic fibrosis 79

for respiratory infections 86

for urinary tract infections 83

for wound infections 74

Phagocytosis 69

Pharmacokinetic aspect of phage therapy 70

Phlebovirus 20

Phosphate 25, 27

dehydrogenase 27

synthase 25

Phosphoheptoseisomerase 25

Plasmid conjugation 126

Plasmodium falciparum 6

Pneumonia 2, 5, 79, 88, 89, 91, 93, 113, 120, 140, 149

and cystic fibrosis 91

hospital-acquired bacterial 79

Poliovirus 151

Polyvinyl alcohol (PVA) 78

Production 123, 124

green fluorescent protein 123

proteolytic enzymes 124

Properties 120, 123

genetic 123

therapeutic 120

Protease inhibitors 141

Proteases 116, 121, 122, 123, 124

Protein(s) 3, 4, 5, 7, 8, 9, 11, 26, 27, 41, 59, 61, 72, 140, 141

antigens 3, 9, 11

cytosolic 8, 9

hypothetical 27

inhibitors 141

nucleocapsid 7

synthesis 140

Proteinuria 39

Proteolysis 121, 122

Proteus mirabilis 84, 85

Pseudomonas aeruginosa 63, 112, 116, 140, 149, 162

Pyocyanin secretion 127

Q

QS-regulated 122, 123

gene encoding AHL synthase 122

violacein biosynthesis 123

QS signalling systems function 116

QS Signals Synthesis 126
 Quorum 111, 119, 127, 128
 quenching (QQ) 119, 128
 sensing inhibitors of amino acid 127
 sensor 111

R

Rattus norvegicus 42
 Reactions, immune-mediated 19, 24
 hypersensitivity 19, 24
 Recombinant 2, 4
 DNA techniques 4
 proteins 2
 Respiratory 86, 92, 93, 141
 infections 86
 syncytial virus infections 141
 tract infections 92, 93
 Restriction fragment length polymorphism (RFLP) 28
 Reverse vaccinology 1, 3, 4, 5, 6, 8, 9, 10, 11
 for intracellular pathogens 6
 Rhamnolipid biosynthesis 125
Rheum palmatum 122
 Ribavirin 141, 142
 influenza virus 141
 RNA polymerase inhibitors 141
 Rogunavirinae 58

S

Salmonella 112, 121, 154
 enterica 112, 154
 typhimurium 121, 154
 Secondary metabolites 120, 123, 125
 Self-replicating-bacteriophages 59
 Sensitized fixed erythrocytes 28
 Sepsis 4, 79
 Serine O-acetyltransferase 27
 Serological test 27
Serratia marcescens 124
 Serum 2, 39, 41
 amyloid A (SAA) 41

 glutamate pyruvate transaminase (SGPT) 39
 lipase 39
 therapy 2
 urea 39
 Severe acute respiratory syndrome 7
 coronavirus 7
 Shigellosis 6
 Signalling pathway 122, 128
 Single-subunit RNA polymerase 57
 Skin 20, 21, 73, 75, 83, 127
 abrasions 20
 lesions 83
 necrosis 21
 pathogens 127
 Smallpox 1, 2
Staphylococcus aureus skin infections 6
 Stomach cancers 140
Streptococcus 5, 112, 120, 160, 162
 agalactiae 160
 mutans 120, 162
 pneumoniae 5, 112
 Streptomycin 64, 140, 149
 Structure 7, 142, 167
 activity relationship (SAR) 142, 167
 based immunoinformatic analysis 7
 Surgery 74, 75
 bone 75
 dental 75
 Surgical wounds 75, 83, 90
 Sustainable 113, 115
 development goals (SDG) 115
 pharmacological progress 113
Syncephalastrum racemosum 149
 Synergistic 33, 70, 86, 128
 effects 33, 86, 128
 Interaction 70
 Synthesis 27, 35, 36, 37, 54, 116, 119, 121, 142, 144, 163
 microwave 163
 nucleic acid 121, 142
 peptidoglycan 27
 Systems 6, 74, 86, 116
 renal 74
 respiratory 6, 86

signalling 116
Syzygium cumini 122

T

Target, mRNA-based vaccine 8
 Therapy 2, 50, 51, 52, 55, 59, 60, 61, 62, 64, 65, 69, 72, 73, 78, 86, 93, 94
 antibiotic 64, 78, 86
 convalescent plasma 2
 Threats, antibiotic-resistant 114
 Thrombocytopenia 23
Thymus vulgaris 123
 Tobacco mosaic virus (TMV) 166
 Transcytosis 66, 67
 Transmembrane endopeptidase 117
 Transpeptidase 35
 Treatment 24, 50, 60, 61, 62, 63, 64, 71, 75, 78, 83, 84, 86, 88, 87, 89, 93, 94
 pneumoniae 64
 prophylactic 87
 wastewater 94
Trichomonas vaginalis 153
 Triglyceride synthase 39
 Tube dilution technique 30

U

Urinary tract infections (UTIs) 5, 62, 83, 84, 85, 86, 91, 92, 113

V

Vaccines 1, 2, 3, 4, 5, 7, 10, 11, 19, 24, 42, 114, 167
 inactivated leptospirosis 19, 24
 leptospiral 42
 technology 5
 Vaccinology 2, 10, 11
 Vancomycin 63, 76, 140, 148
 Varicella-zoster virus infections 141
Variovorax paradoxus 127
Vibrio 6, 52, 121, 126
 cholerae 6, 52

fischeri 126
harveyi and hindrance of biofilm formation 121
 Viral diseases 2, 6, 167
 emerging 2, 167
 Viral vaccines 6
 Virulence 2, 119, 126, 127
 genes 127
 pathogen's 2
 reducing bacterial 126
 system 119
 Virulence factors 27, 125, 126
 pathogenicity 27
 production 125, 126
 Virus 7, 57, 141, 151, 153, 165, 166
 anti-tobacco mosaic 166
 chikungunya 153
 infectious hematopoietic necrosis 166

W

Water 20, 21, 30, 40, 42, 52, 81, 89
 contaminated 42
 polluted 21
 sewage 89
 Web-based 9, 8
 application 9
 software programs 8
 Workers 20, 22, 42
 meat industry 22
 sanitation 22
 World health organization (WHO) 5, 19, 21, 74, 76, 111, 113, 114, 115, 140
 Wound infections 5, 74, 76

X

X-ray crystallography 11

Y

Yersinia species 58

Z

Zika virus 167



PARVESH SINGH

Dr. Parvesh Singh is an NRF-rated researcher in the School of Chemistry and Physics (SCP) at the University of KwaZulu-Natal (UKZN), Durban (South Africa). After completing his Ph.D. degree (Organic Chemistry), in 2006, from the Guru Nanak Dev University (India), Dr. Singh joined a pharmaceutical company (Jubilant Organosys) as a Research Scientist and then moved to South Africa to pursue his Post-doctoral studies at the Durban University of Technology. In 2014, Dr. Singh was appointed as a Senior Lecturer at UKZN and then promoted to Associate Professor in the same institution. Dr. Singh's research primarily focuses on the synthesis of heterocyclic scaffolds and their biological testing and molecular modelling studies. Dr. Singh is a recipient of a prestigious DST-NRF Free-standing fellowship and has been featured as one of the emerging researchers in South Africa by the National Research Foundation (NRF). He has also been a recipient of top University and College research awards on several occasions. He has co-authored more than 100 research papers in top tier international journals and serving as an editorial board member and ambassador for several reputed publishers.



VIPAN KUMAR

Dr. Vipin Kumar Ph.D. has been working as an Assistant Professor in the Department of Chemistry, Guru Nanak Dev University, Amritsar, since 2009. He obtained his Ph.D. with Prof. Mohinder P Mahajan in the Department of Applied Chemistry, GNDU. In 2007, he moved to the University of Cape Town (UCT), South Africa, to pursue his post-doctoral studies with Prof. Kelly Chibale. In 2015, he was awarded a research fellowship from Carl Tryggers research foundation, Sweden to carry out research at University of Umea, Sweden. His research interests include the development of diverse synthetic protocols for the synthesis of novel molecular frameworks targeting tropical infections. He has also been engaged in the utilization of b-lactam synthon protocols for the synthesis of functionally decorated and biologically relevant heterocycles with medicinal potential.



RAJSHEKHAR KARPOORMATH

Prof. Rajshekhar Karpoormath graduated with his Ph.D. (2013) from the School of Chemistry and Physics, University of KwaZulu-Natal (UKZN), Durban, South Africa. He is currently an Associate Professor and Academic Leader of Research in the College of Health Sciences, UKZN. He is also a nationally recognized rated researcher by National Research Foundation-South Africa (NRF-SA). Prof Karpoormath started his independent research carrier in 2014 and established a research group, Synthetic and Medicinal Chemistry Research Group (SMCRG), at UKZN. Over the years, he has successfully secured several national and institutional grants and has established a well-equipped Drug Discovery Laboratory at UKZN. His research work is focused on target-based drug design and synthesis, Methodology development, and development of nanomaterial-based electrochemical biosensors. Since 2014, his research group has published more than 100 peer-reviewed articles in international journals, four book chapters, and two patents. He has successfully graduated 23 postgraduate students (12 Ph.Ds. and 11 Masters) since 2014. He is one of the top researchers at UKZN and was the recipient of several awards in recognition of his achievements.